Wall Street analysts forecast that Shire PLC (NASDAQ:SHPG) will announce $3.77 billion in sales for the current quarter, according to Zacks. Four analysts have made estimates for Shire PLC’s earnings. The highest sales estimate is $3.80 billion and the lowest is $3.73 billion. Shire PLC posted sales of $3.45 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 9.3%. The business is scheduled to issue its next quarterly earnings report before the market opens on Friday, October 27th.
On average, analysts expect that Shire PLC will report full-year sales of $3.77 billion for the current fiscal year, with estimates ranging from $15.00 billion to $15.14 billion. For the next financial year, analysts anticipate that the company will report sales of $15.89 billion per share, with estimates ranging from $15.22 billion to $16.55 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Shire PLC.
Shire PLC (NASDAQ:SHPG) last announced its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%.
Several research firms recently commented on SHPG. Cantor Fitzgerald set a $222.00 price target on shares of Shire PLC and gave the company a “buy” rating in a report on Saturday, July 1st. Jefferies Group LLC restated a “hold” rating and issued a $206.00 price target (down previously from $216.00) on shares of Shire PLC in a report on Wednesday, August 9th. Barclays PLC lowered shares of Shire PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, August 11th. Stifel Nicolaus restated a “buy” rating and issued a $245.00 price target on shares of Shire PLC in a report on Sunday, October 8th. Finally, Sanford C. Bernstein restated a “market perform” rating and issued a $210.00 price target on shares of Shire PLC in a report on Thursday, July 13th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $220.91.
TRADEMARK VIOLATION NOTICE: This piece was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://sportsperspectives.com/2017/10/17/zacks-brokerages-anticipate-shire-plc-shpg-will-announce-quarterly-sales-of-3-77-billion.html.
A number of institutional investors have recently added to or reduced their stakes in SHPG. BlackRock Inc. boosted its holdings in Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after purchasing an additional 1,400,275 shares during the period. Janus Henderson Group PLC boosted its holdings in Shire PLC by 22,560.3% in the second quarter. Janus Henderson Group PLC now owns 1,286,881 shares of the biopharmaceutical company’s stock worth $212,683,000 after purchasing an additional 1,281,202 shares during the period. Glenview Capital Management LLC acquired a new position in Shire PLC in the first quarter worth $176,927,000. New South Capital Management Inc. acquired a new position in Shire PLC in the first quarter worth $87,954,000. Finally, Northern Trust Corp boosted its holdings in Shire PLC by 45.5% in the second quarter. Northern Trust Corp now owns 1,307,339 shares of the biopharmaceutical company’s stock worth $216,064,000 after purchasing an additional 408,843 shares during the period. 19.24% of the stock is owned by hedge funds and other institutional investors.
Shares of Shire PLC (NASDAQ:SHPG) opened at 155.28 on Tuesday. Shire PLC has a 52 week low of $139.36 and a 52 week high of $192.64.
The business also recently declared a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be paid a $0.1527 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s dividend payout ratio (DPR) is presently 41.07%.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.